BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 28009435)

  • 21. Anti-CD22/CD20 Bispecific antibody with enhanced trogocytosis for treatment of Lupus.
    Rossi EA; Chang CH; Goldenberg DM
    PLoS One; 2014; 9(5):e98315. PubMed ID: 24841238
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma.
    Dornan D; Bennett F; Chen Y; Dennis M; Eaton D; Elkins K; French D; Go MA; Jack A; Junutula JR; Koeppen H; Lau J; McBride J; Rawstron A; Shi X; Yu N; Yu SF; Yue P; Zheng B; Ebens A; Polson AG
    Blood; 2009 Sep; 114(13):2721-9. PubMed ID: 19633198
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ADCT-602, a Novel PBD Dimer-containing Antibody-Drug Conjugate for Treating CD22-positive Hematologic Malignancies.
    Zammarchi F; Havenith KE; Sachini N; Janghra N; Chivers S; Idusogie E; Gaudio E; Tarantelli C; Bertelli F; Santos K; Tyrer P; Corbett S; Spriano F; Golino G; Cascione L; Bertoni F; Hartley JA; van Berkel PH
    Mol Cancer Ther; 2024 Apr; 23(4):520-531. PubMed ID: 38324336
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characterization of anti-CD79b/CD3 bispecific antibody, a potential therapy for B cell malignancies.
    Wang J; Li C; He K; Kuang Z; Lu J; Yao Y; He F; Li N; Li L; Fu F; Wu Z; Zhou S; Kang D; Qiu X; Wu M; Liu Y; Cao X; Xu M; Chen B; Wu W; Guo F
    Cancer Immunol Immunother; 2023 Feb; 72(2):493-507. PubMed ID: 35963895
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I Study of the Anti-CD22 Antibody-Drug Conjugate Pinatuzumab Vedotin with/without Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma.
    Advani RH; Lebovic D; Chen A; Brunvand M; Goy A; Chang JE; Hochberg E; Yalamanchili S; Kahn R; Lu D; Agarwal P; Dere RC; Hsieh HJ; Jones S; Chu YW; Cheson BD
    Clin Cancer Res; 2017 Mar; 23(5):1167-1176. PubMed ID: 27601593
    [No Abstract]   [Full Text] [Related]  

  • 26. Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selection.
    Polson AG; Calemine-Fenaux J; Chan P; Chang W; Christensen E; Clark S; de Sauvage FJ; Eaton D; Elkins K; Elliott JM; Frantz G; Fuji RN; Gray A; Harden K; Ingle GS; Kljavin NM; Koeppen H; Nelson C; Prabhu S; Raab H; Ross S; Slaga DS; Stephan JP; Scales SJ; Spencer SD; Vandlen R; Wranik B; Yu SF; Zheng B; Ebens A
    Cancer Res; 2009 Mar; 69(6):2358-64. PubMed ID: 19258515
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Binding to CD20 by anti-B1 antibody or F(ab')(2) is sufficient for induction of apoptosis in B-cell lines.
    Cardarelli PM; Quinn M; Buckman D; Fang Y; Colcher D; King DJ; Bebbington C; Yarranton G
    Cancer Immunol Immunother; 2002 Mar; 51(1):15-24. PubMed ID: 11845256
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Asian race and origin have no clinically meaningful effects on polatuzumab vedotin pharmacokinetics in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
    Shi R; Lu T; Ku G; Ding H; Saito T; Gibiansky L; Agarwal P; Li X; Jin JY; Girish S; Miles D; Li C; Lu D
    Cancer Chemother Pharmacol; 2020 Sep; 86(3):347-359. PubMed ID: 32770353
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Production and characterization of a camelid single domain anti-CD22 antibody conjugated to DM1.
    Ziaei V; Ghassempour A; Davami F; Azarian B; Behdani M; Dabiri H; Habibi-Anbouhi M
    Mol Cell Biochem; 2024 Mar; 479(3):579-590. PubMed ID: 37129769
    [TBL] [Abstract][Full Text] [Related]  

  • 30. B-cell inhibition by cross-linking CD79b is superior to B-cell depletion with anti-CD20 antibodies in treating murine collagen-induced arthritis.
    Brühl H; Cihak J; Talke Y; Rodriguez Gomez M; Hermann F; Goebel N; Renner K; Plachý J; Stangassinger M; Aschermann S; Nimmerjahn F; Mack M
    Eur J Immunol; 2015 Mar; 45(3):705-15. PubMed ID: 25471597
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CD22-Binding Synthetic Sialosides Regulate B Lymphocyte Proliferation Through CD22 Ligand-Dependent and Independent Pathways, and Enhance Antibody Production in Mice.
    Matsubara N; Imamura A; Yonemizu T; Akatsu C; Yang H; Ueki A; Watanabe N; Abdu-Allah H; Numoto N; Takematsu H; Kitazume S; Tedder TF; Marth JD; Ito N; Ando H; Ishida H; Kiso M; Tsubata T
    Front Immunol; 2018; 9():820. PubMed ID: 29725338
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Extensive crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in human lymphoma cells.
    Chang CH; Wang Y; Gupta P; Goldenberg DM
    MAbs; 2015; 7(1):199-211. PubMed ID: 25484043
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of non-Hodgkin's lymphoma xenografts with the HB22.7 anti-CD22 monoclonal antibody and phosphatase inhibitors improves efficacy.
    O'Donnell RT; Pearson D; McKnight HC; Ma YP; Tuscano JM
    Cancer Immunol Immunother; 2009 Oct; 58(10):1715-22. PubMed ID: 19294384
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CD22 ligation inhibits downstream B cell receptor signaling and Ca(2+) flux upon activation.
    Sieger N; Fleischer SJ; Mei HE; Reiter K; Shock A; Burmester GR; Daridon C; Dörner T
    Arthritis Rheum; 2013 Mar; 65(3):770-9. PubMed ID: 23233360
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bispecific anti-CD20/22 antibodies inhibit B-cell lymphoma proliferation by a unique mechanism of action.
    Qu Z; Goldenberg DM; Cardillo TM; Shi V; Hansen HJ; Chang CH
    Blood; 2008 Feb; 111(4):2211-9. PubMed ID: 18025153
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Trastuzumab-monomethyl auristatin E conjugate exhibits potent cytotoxic activity in vitro against HER2-positive human breast cancer.
    Abdollahpour-Alitappeh M; Lotfinia M; Bagheri N; Sineh Sepehr K; Habibi-Anbouhi M; Kobarfard F; Balalaie S; Foroumadi A; Abbaszadeh-Goudarzi G; Abbaszadeh-Goudarzi K; Abolhassani M
    J Cell Physiol; 2019 Mar; 234(3):2693-2704. PubMed ID: 30246298
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antibody-targeted chemotherapy of B-cell lymphoma using calicheamicin conjugated to murine or humanized antibody against CD22.
    DiJoseph JF; Popplewell A; Tickle S; Ladyman H; Lawson A; Kunz A; Khandke K; Armellino DC; Boghaert ER; Hamann P; Zinkewich-Peotti K; Stephens S; Weir N; Damle NK
    Cancer Immunol Immunother; 2005 Jan; 54(1):11-24. PubMed ID: 15693135
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification and characterization of fully human anti-CD22 monoclonal antibodies.
    Xiao X; Ho M; Zhu Z; Pastan I; Dimitrov DS
    MAbs; 2009; 1(3):297-303. PubMed ID: 20065646
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antibody-drug conjugates for previously treated aggressive lymphomas: focus on polatuzumab vedotin.
    Burke JM; Morschhauser F; Andorsky D; Lee C; Sharman JP
    Expert Rev Clin Pharmacol; 2020 Oct; 13(10):1073-1083. PubMed ID: 32985934
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.